Abstract
Cisatracurium besilate, one of the 10 stereoisomers that comprise atracurium besilate, is a nondepolarising neuromuscular blocking agent with an intermediate duration of action. Following a 5- to 10-sec intravenous bolus dose of cisatracurium besilate to healthy young adult surgical patients, elderly patients and patients with renal or hepatic failure, the concentration versus time profile of cisatracurium besilate is best characterised by a 2-compartment model. The volume of distribution (Vd) of cisatracurium besilate is small because of its relatively large molecular weight and high polarity.
Cisatracurium besilate undergoes Hofmann elimination, a process dependent on pH and temperature. Unlike atracurium besilate, cisatracurium besilate does not appear to be degraded directly by ester hydrolysis. Hofmann elimination, an organ independent elimination pathway, occurs in plasma and tissue, and is responsible for approximately 77% of the overall elimination of cisatracurium besilate.
The total body clearance (CL), steady-state Vd and elimination half-life of cisatracurium besilate in patients with normal organ function are approximately 0.28 L/h/kg (4.7 ml/min/kg), 0.145 L/kg and 25 minutes, respectively. The magnitude of interpatient variability in the CL of cisatracurium besilate is low (16%), a finding consistent with the strict physiological control of the factors that effect the Hofmann elimination of cisatracurium besilate (i.e. temperature and pH). There is a unique relationship between plasma clearance and Vd because the primary elimination pathway for cisatracurium besilate is not dependent on organ function.
There are minor differences in the pharmacokinetics of cisatracurium besilate in various patient populations. These differences are not associated with clinically significant differences in the recovery profile of cisatracurium besilate, but may be associated with differences in the time to onset of neuromuscular block.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Welch RM, Brown A, Ravitch J, et al. The in vitro degradation of cisatracurium, the R, cis-R’-isomer of atracurium, in human and rat plasma. Clin Pharmacol Ther 1995 Aug; 58: 132–42.
Belmont MR, Lien CA, Quessy S, et al. The clinical neuromuscular pharmacology of 51 W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology 1995 May; 82: 1139–45.
Fisher DM, Rosen JI. A pharmacokinetic explanation for increasing recovery time following larger or repeated doses of non-depolarizing muscle relaxants. Anesthesiology 1986 Sep; 65: 286–91.
Kopman A. Pancuronium, gallamine, and d-tubocurarine compared: is speed of onset inversely related to drug potency? Anesthesiology 1989 Jun; 70: 915–20.
Lien CA, Belmont MR, Abalos A, et al. The cardiovascular effects and histamine-releasing properties of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology 1995 May; 82: 1131–8.
Bryson HM, Faulds D. Cisatracurium besilate: a review of its pharmacology and clinical potential in anaesthetic practice. Drugs 1997 May; 53: 848–66.
Ornstein E, Lien CA, Matteo RS, et al. Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. Anesthesiology 1996 Mar; 84: 520–5.
DeWolf AM, Freeman JA, Scott VL, et al. Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. Br J Anaesth 1996 May; 76: 624–8.
Lien CA, Schmith VD, Belmont MR, et al. Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/op-ioid/barbiturate anesthesia. Anesthesiology 1996 Feb; 84: 300–8.
Sorooshian SS, Stafford MA, Eastwood NB, et al. Pharmacokinetics and pharmacodynamics of cisatracurium in young and elderly adult patients. Anesthesiology 1996 May; 84: 1083–91.
Schmith VD, Phillips L, Kisor DF, et al. Pharmacokinet-ics/pharmacodynamics of cisatracurium in healthy adult patients. Curr Opin Anesthesiol 1996; 9 Suppl. 1: S9–15.
Schmith VD, Fiedler-Kelly J, Phillips L, et al. Prospective use of population pharmacokinetics/pharmacodynamics in the development of cisatracurium. Pharm Res 1997 Jan; 14: 91–7.
Kisor DF, Schmith VD, Wargin WA, et al. Importance of the organ-independent elimination of cisatracurium. Anesth Analg 1996 Nov; 83: 1065–71.
Nakashima E, Benet LZ. General treatment of mean residence time, clearance, and volume parameters in linear mammillary models with elimination from any compartment. J Pharmacokinet Biopharm 1988 Oct; 16: 475–92.
Hull CJ. A model for atracurium? Br J Anaesth 1983 Feb; 55: 95–6.
Data on file, Glaxo Wellcome Incorporated.
Fisher DM, Canfell PC, Fahey MR, et al. Elimination of atracurium in humans: Contribution of Hofmann elimination and ester hydrolysis versus organ-based elimination. Anesthesiology 1986 Jul; 65: 6–12.
Fisher DM. (Almost) everything you learned about pharmacokinetics was (somewhat) wrong! Anesth Analg 1996 Nov; 83: 901–3.
Wilkinson GR. Clearance approaches in pharmacology. Pharmacol Rev 1987 Mar; 39: 1–47.
Eastwood NB, Boyd AH, Parker CJR, et al. Pharmacokinetics of 1R-cis 1′R-cis atracurium besylate (51W89) and plasma laudanosine concentrations in health and chronic renal failure. Br J Anaesth 1995 Oct; 75: 431–5.
Schmautz E, Deriaz H, Vrillan MR, et al. Evaluation of 51W89 for endotracheal intubation in surgical patients during N2O2/propofol anesthesia [abstract]. Anesthesiology 1994; 81: A1081.
Lepage JY, Malinovsky JM, Malinge M, et al. Comparison of equipotent doses of 51W89 and atracurium. Anes Analg 1996 Oct; 83: 823–9.
Bergeron L, Varin F, Berrill A, et al. Kinetics and dynamics of cisatracurium at 3 doses in anaesthetized patients [abstract]. Anesthesiology 1996 Sep; 85: A324.
Ducharme J, Varin F, Bevan DR, et al. Importance of early blood sampling on vecuronium pharmacokinetics and pharmacodynamic parameters. Clin Pharmacokinet 1993 Jun; 34: 507–18.
Donati F, Varin F, Ducharme J, et al. Pharmacokinetics and pharmacodynamics of atracurium obtained with arterial and venous samples. Clin Pharmacol Ther 1991 May; 49: 515–22.
Tran TV, Varin F, Fiset P. Pharmacokinetic-pharmacodynamic modeling of a short cisatracurium infusion in ASA I and II patients under propofol/sufentanil/N2O anesthesia [abstract]. Anesthesiology 1996 Sep; 85: A325.
Schmith VD, Fiedler-Kelly J, Phillips L, et al. Dose proportionality of cisatracurium. J Clin Pharmacol 1997 Jul; 37: 625–9.
Wright PM, Fisher DM. Can bioavailability of low-variance drugs be estimated with an unpaired, sparse sampling design? Clin Pharmacol Ther 1998 Apr; 63: 437–43.
Bluestein LS, Stinson Jr LW, Lennon RL, et al. Evaluation of cisatracurium, a new neuromuscular blocking agent, for tracheal intubation. Can J Anaesth 1996 Sep; 43: 925–31.
Berrill A, Kahwaji R, Bevan D, et al. ‘Pharmacodynamic half-life’ of cisatracurium [abstract]. Anesthesiology 1996 Sep; 85: A833.
Boyd AH, Eastwood NB, Parker CJR, et al. Pharmacodynamics of the 1Rcis -1′Rcis isomer of atracurium (51W89) in health and chronic renal failure. Br J Anaesth 1995 Apr; 74: 400–4.
Pavlin EG, Forrest AP, Howard M, et al. Prior administration of succinylcholine does not affect the duration of NIMBEX (51W89) neuromuscular blockade. Anesth Anal 1995; 80 Suppl. 1: S374.
Sheiner LB, Stanski DR, Vozeh S, et al. Simultaneous modeling of the pharmacokinetics and pharmacodynamics: application to D-tubocurarine. Clin Pharmacol Ther 1979 Mar; 25: 358–71.
Eger EI. The pharmacology of isoflurane. Br J Anaesth 1984; 56 Suppl. 1: 71s–99s.
Cisatracurium prescribing information. Research Triangle Park (NC): Glaxo Wellcome Inc., 1995 Dec.
Boyd AH, Eastwood NB, Parker CJR, et al. Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. Br J Anaesth 1996 Mar; 76: 382–8.
Phillips L, Schmith VD, Brandom BW, et al. Population pharmacokinetics/pharmacodynamics (PK/PD) of 51W89 in healthy pediatrie patients [abstract]. Clin Pharmacol Ther 1995; 57: 213.
Hunter JM, DeWolf A. The pharmacodynamics and pharmacokinetics of cisatracurium in patients with renal or hepatic failure. Curr Opin Anesthesiol 1996; 9 Suppl. 1: S40–4.
Brandom BW, Woelfel SK, Gronert BJ, et al. Effects of 51W89 (cisatracurium) in children during halothane nitrous oxide anesthesia [abstract]. Anesthesiology 1995 Sep; 83: A921.
O’Neill BL, Foley ER. The neuromuscular blocking effects of cisatracurium in children during sevoflurane anesthesia [abstract]. Anesthesiology 1996 Sep; 85: A1058.
Meretoja OA, Taivainen T, Wirtavuori K. Cisatracurium during halothane and balanced anaesthesia in children. Paediatr Anaesth 1996; 6: 373–8.
Prielipp RC, Coursin DB, Scuderi PE, et al. Comparison of the infusion requirements and recovery profiles of vecuronium and cisatracurium 51W89 in intensive care unit patients. Anesth Analg 1995 Jul; 81: 3–12.
Newman PJ, Quinn AC, Grounds RM, et al. A comparison of cisatracurium (51W89) and atracurium by infusion in critically ill patients. Crit Care Med 1997 Jul; 25: 1139–42.
Pearson AJ, Harper NJ, Pollard BJ. The infusion requirements and recovery characteristics of cisatracurium or atracurium in intensive care patients. Int Care Med 1996 Jul; 22: 694–8.
Tobias JD. Increased cisatracurium requirements during prolonged administration to a child. Can J Anaesth 1997; 44: 83–4.
Shi WZ, Fahey MR, Fisher DM, et al. Modification of central nervous system effects of laudanosine by inhalation anesthesia. Br J Anaesth 1989 Nov; 63: 598–600.
Hennis PJ, Fahey MR, Miller RD, et al. Pharmacology of laudanosine in dogs [abstract]. Anesthesiology 1984; 61: A305.
Ingram MD, Sclabassi RJ, Cook DR, et al. Cardiovascular and electroencephalographic effects of laudanosine in ‘nephrectomized’ cats. Br J Anaesth 1986; 58 Suppl. 1: 14s–18s.
Chappie DJ, Miller AA, Ward JB, et al. Cardiovascular and neurological effects of laudanosine: studies in mice and rats, and in conscious and anesthetized dogs. Br J Anaesth 1987; 59: 218–25.
Smith CE, van Miert MM, Parker CJR, et al. A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1′R-cis isomer of atracurium, with atracurium besylate in healthy patients. Anaesthesia 1997 Sep; 52: 833–41.
Fahey MR, Rupp SM, Canfell C, et al. Effect of renal failure on laudanosine excretion in man. Br J Anaesth 1985; 57: 1049–51.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kisor, D.F., Schmith, V.D. Clinical Pharmacokinetics of Cisatracurium Besilate. Clin Pharmacokinet 36, 27–40 (1999). https://doi.org/10.2165/00003088-199936010-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199936010-00003